Scaling Up For Cell And Gene Therapies

The promise of cell and gene therapies has moved beyond rare diseases and is now poised to revolutionize treatment for a wider range of conditions. But this therapeutic revolution hinges on our ability to manufacture sufficient cell doses. Current production methods simply can't meet the projected demand, making bioreactor scale-up not just advantageous, but absolutely essential. Scaling up, however, isn't as simple as increasing vessel size.

Allogeneic cell therapies face significant hurdles, from the complexities of hydrodynamic conditions within larger bioreactors to the ever-present pressure of media costs. Reproducibility and robust process design are also critical, yet often elusive, at larger scales. These challenges are slowing progress and threatening to limit the potential of these life-changing therapies.

Want to learn how to overcome these obstacles and unlock the true potential of cell and gene therapy manufacturing? Watch this webinar to explore effective strategies for optimizing scale-up in a cost-effective and efficient manner.